Nevro Aquires Vyrsa Technologies

Vyrsa spinal technologies

Nevro acquired Vyrsa Technologies, developer of a minimally invasive treatment option for patients suffering from chronic sacroiliac (SI) joint pain.

Nevro paid $40 million at closing and will pay up to an additional $35 million in cash or stock tied to achievement of certain development and sales milestones.

Vyrsa manufactures and supports...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us